Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design. (Q39935569)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857185%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

title

Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857185%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference

1 reference

1 reference

3

Jeffrey Schlom

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857185%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

4

James L Gulley

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857185%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

author name string

Ravi A Madan

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857185%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Mahsa Mohebtash

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857185%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

language of work or name

English

0 references

publication date

1 January 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857185%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Biological Therapy

11 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857185%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857185%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857185%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

page(s)

19-28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857185%20AND%20SRC:MED&resulttype=core&format=json

Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results

11 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

Androgen deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

PSA-based vaccines for the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

Molecular cloning and sequence analysis of cDNA encoding human prostatic acid phosphatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

NGEP, a gene encoding a membrane protein detected only in prostate cancer and normal prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

Recognition of prostate and breast tumor cells by helper T lymphocytes specific for a prostate and breast tumor-associated antigen, TARP

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

Poxvirus vaccines for cancer and HIV therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

Human B cells that hyperexpress a triad of costimulatory molecules via avipox-vector infection: an alternative source of efficient antigen-presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

Transforming growth factor-beta and the immune response to malignant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

Indoleamine 2,3-dioxygenase in immune suppression and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

Natural history of progression after PSA elevation following radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

RECIST revisited: a review of validation studies on tumour assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

Tumour vaccine associated lymphadenopathy and false positive positron emission tomography scan changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

Immunoregulatory T cells in cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

Regulatory T cells: key controllers of immunologic self-tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

GM-CSF-induced CD11c+CD8a--dendritic cells facilitate Foxp3+ and IL-10+ regulatory T cell expansion resulting in suppression of autoimmune thyroiditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

Granulocyte-macrophage colony-stimulating factor prevents diabetes development in NOD mice by inducing tolerogenic dendritic cells that sustain the suppressive function of CD4+CD25+ regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903321421

A triad of costimulatory molecules synergize to amplify T-cell activation

21 January 2018

1 reference

12 December 2020

Tumor-specific CD4(+) suppressor T-cell clone capable of inhibiting rejection of syngeneic sarcoma in A/J mice

1 reference

12 December 2020

Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells

1 reference

12 December 2020

The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma

1 reference

12 December 2020

Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.

1 reference

12 December 2020

Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells

1 reference

12 December 2020

Allogeneic whole-cell vaccine: a phase I/II study in men with hormone-refractory prostate cancer

1 reference

12 December 2020

Technology evaluation: APC-8015, Dendreon.

1 reference

12 December 2020

Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation

1 reference

12 December 2020

Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer.

1 reference

12 December 2020

Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation

1 reference

12 December 2020

Immunotherapy for prostate cancer

1 reference

12 December 2020

Distribution of CD4+CD25high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer

1 reference

12 December 2020

Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer

1 reference

12 December 2020

Prostate Specific Antigen: A Critical Assessment of the Most Useful Tumor Marker for Adenocarcinoma of the Prostate

1 reference

12 December 2020

In vitro expansion improves in vivo regulation by CD4+CD25+ regulatory T cells

1 reference

12 December 2020

Prostate tumor biology and cell kinetics--theory

1 reference

12 December 2020

Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases

1 reference

12 December 2020

Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide

1 reference

12 December 2020

Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen

1 reference

12 December 2020

10.1517/14712590903321421

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857185%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857185%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

PubMed publication ID

19857185

1 reference